JPWO2020176794A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020176794A5 JPWO2020176794A5 JP2021550149A JP2021550149A JPWO2020176794A5 JP WO2020176794 A5 JPWO2020176794 A5 JP WO2020176794A5 JP 2021550149 A JP2021550149 A JP 2021550149A JP 2021550149 A JP2021550149 A JP 2021550149A JP WO2020176794 A5 JPWO2020176794 A5 JP WO2020176794A5
- Authority
- JP
- Japan
- Prior art keywords
- drug conjugate
- antibody drug
- amino acid
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000611 antibody drug conjugate Substances 0.000 claims description 275
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 275
- 230000035772 mutation Effects 0.000 claims description 108
- 239000012634 fragment Substances 0.000 claims description 45
- 239000000427 antigen Substances 0.000 claims description 44
- 102000036639 antigens Human genes 0.000 claims description 44
- 108091007433 antigens Proteins 0.000 claims description 44
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 37
- 239000003112 inhibitor Substances 0.000 claims description 36
- 230000001225 therapeutic effect Effects 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- GTBCXYYVWHFQRS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)pentanoate Chemical compound C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CCC1=O GTBCXYYVWHFQRS-UHFFFAOYSA-N 0.000 claims description 12
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 9
- VRDGQQTWSGDXCU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-iodoacetate Chemical compound ICC(=O)ON1C(=O)CCC1=O VRDGQQTWSGDXCU-UHFFFAOYSA-N 0.000 claims description 8
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 claims description 8
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 claims description 8
- OWGOYNSFBOQRRO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-cyclobutyl-4-(pyridin-2-yldisulfanyl)butanoate Chemical compound C1(CCC1)C(CCC(=O)ON1C(CCC1=O)=O)SSC1=NC=CC=C1 OWGOYNSFBOQRRO-UHFFFAOYSA-N 0.000 claims description 8
- UTZTZUCTABINRD-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-cyclopropyl-4-(pyridin-2-yldisulfanyl)butanoate Chemical compound C1(CC1)C(CCC(=O)ON1C(CCC1=O)=O)SSC1=NC=CC=C1 UTZTZUCTABINRD-UHFFFAOYSA-N 0.000 claims description 8
- LQILVUYCDHSGEU-UHFFFAOYSA-N 4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)CCC1CN1C(=O)C=CC1=O LQILVUYCDHSGEU-UHFFFAOYSA-N 0.000 claims description 8
- -1 6-maleimidocaproyl Chemical group 0.000 claims description 8
- 101710181812 Methionine aminopeptidase Proteins 0.000 claims description 8
- 102000029749 Microtubule Human genes 0.000 claims description 8
- 108091022875 Microtubule Proteins 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 8
- 210000004688 microtubule Anatomy 0.000 claims description 8
- 239000002105 nanoparticle Substances 0.000 claims description 8
- 239000004308 thiabendazole Substances 0.000 claims description 8
- 239000003431 cross linking reagent Substances 0.000 claims description 7
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims description 7
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 claims description 5
- 239000008380 degradant Substances 0.000 claims description 5
- 238000010362 genome editing Methods 0.000 claims description 5
- 150000003384 small molecules Chemical class 0.000 claims description 5
- PVBORIXVWRTHOZ-UHFFFAOYSA-N (2,5-dioxopyrrol-1-yl)methyl cyclohexanecarboxylate Chemical compound C1CCCCC1C(=O)OCN1C(=O)C=CC1=O PVBORIXVWRTHOZ-UHFFFAOYSA-N 0.000 claims description 4
- NFJWAGOKMMRHHY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[2-[[2-[[2-[4-(2,5-dioxopyrrol-1-yl)butanoylamino]acetyl]amino]acetyl]amino]acetyl]amino]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCNC(=O)CNC(=O)CNC(=O)CNC(=O)CCCN1C(=O)C=CC1=O NFJWAGOKMMRHHY-UHFFFAOYSA-N 0.000 claims description 4
- RBVOVMPKOQOCFL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-cyclobutyl-3-(pyridin-2-yldisulfanyl)propanoate Chemical compound C1(CCC1)C(CC(=O)ON1C(CCC1=O)=O)SSC1=NC=CC=C1 RBVOVMPKOQOCFL-UHFFFAOYSA-N 0.000 claims description 4
- PAXQVFMIUZJDOC-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-cyclopropyl-3-(pyridin-2-yldisulfanyl)propanoate Chemical compound C1(CC1)C(CC(=O)ON1C(CCC1=O)=O)SSC1=NC=CC=C1 PAXQVFMIUZJDOC-UHFFFAOYSA-N 0.000 claims description 4
- CTIFFJZCLXQJHT-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-cyclobutyl-4-pyridin-2-ylsulfanylbutanoate Chemical compound C1(CCC1)C(CCC(=O)ON1C(CCC1=O)=O)SC1=NC=CC=C1 CTIFFJZCLXQJHT-UHFFFAOYSA-N 0.000 claims description 4
- ZHCYUAYWLHQPTD-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-cyclohexyl-4-pyridin-2-ylsulfanylbutanoate Chemical compound C1(CCCCC1)C(CCC(=O)ON1C(CCC1=O)=O)SC1=NC=CC=C1 ZHCYUAYWLHQPTD-UHFFFAOYSA-N 0.000 claims description 4
- WEASHVXTHUPVLZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-cyclopropyl-4-pyridin-2-ylsulfanylbutanoate Chemical compound C1(CC1)C(CCC(=O)ON1C(CCC1=O)=O)SC1=NC=CC=C1 WEASHVXTHUPVLZ-UHFFFAOYSA-N 0.000 claims description 4
- OWSHKQHZDSXYRH-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-pyridin-2-ylsulfanylhexanoate Chemical compound N1=C(C=CC=C1)SC(CCC(=O)ON1C(CCC1=O)=O)CC OWSHKQHZDSXYRH-UHFFFAOYSA-N 0.000 claims description 4
- MPHYKSLFRQXIQE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 5-ethyl-4-pyridin-2-ylsulfanylheptanoate Chemical compound C(C)C(C(CCC(=O)ON1C(CCC1=O)=O)SC1=NC=CC=C1)CC MPHYKSLFRQXIQE-UHFFFAOYSA-N 0.000 claims description 4
- ORKRNTKKXLJEOC-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 5-methyl-4-pyridin-2-ylsulfanylhexanoate Chemical compound CC(C(CCC(=O)ON1C(CCC1=O)=O)SC1=NC=CC=C1)C ORKRNTKKXLJEOC-UHFFFAOYSA-N 0.000 claims description 4
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 claims description 4
- GWEVSJHKQHAKNW-UHFFFAOYSA-N 4-[[1-(2,5-dioxopyrrolidin-1-yl)-2h-pyridin-2-yl]disulfanyl]-2-sulfobutanoic acid Chemical compound OC(=O)C(S(O)(=O)=O)CCSSC1C=CC=CN1N1C(=O)CCC1=O GWEVSJHKQHAKNW-UHFFFAOYSA-N 0.000 claims description 4
- 229940121819 ATPase inhibitor Drugs 0.000 claims description 4
- OMNVYXHOSHNURL-WPRPVWTQSA-N Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMNVYXHOSHNURL-WPRPVWTQSA-N 0.000 claims description 4
- 101100004408 Arabidopsis thaliana BIG gene Proteins 0.000 claims description 4
- 239000012664 BCL-2-inhibitor Substances 0.000 claims description 4
- 229940123711 Bcl2 inhibitor Drugs 0.000 claims description 4
- LRBVHYGKNRIQPP-UHFFFAOYSA-N C1(CCCC1)C(CCC(=O)ON1C(CCC1=O)=O)SC1=NC=CC=C1 Chemical compound C1(CCCC1)C(CCC(=O)ON1C(CCC1=O)=O)SC1=NC=CC=C1 LRBVHYGKNRIQPP-UHFFFAOYSA-N 0.000 claims description 4
- UAKFFGIBVYYHAF-UHFFFAOYSA-N CC(C(CCC(=O)ON1C(CCC1=O)=O)SC1=NC=CC=C1)CC Chemical compound CC(C(CCC(=O)ON1C(CCC1=O)=O)SC1=NC=CC=C1)CC UAKFFGIBVYYHAF-UHFFFAOYSA-N 0.000 claims description 4
- 108091033409 CRISPR Proteins 0.000 claims description 4
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims description 4
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims description 4
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 claims description 4
- 239000012624 DNA alkylating agent Substances 0.000 claims description 4
- 239000012623 DNA damaging agent Substances 0.000 claims description 4
- 239000012625 DNA intercalator Substances 0.000 claims description 4
- 239000012626 DNA minor groove binder Substances 0.000 claims description 4
- 102100024746 Dihydrofolate reductase Human genes 0.000 claims description 4
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 4
- 101100485279 Drosophila melanogaster emb gene Proteins 0.000 claims description 4
- 102100029095 Exportin-1 Human genes 0.000 claims description 4
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 claims description 4
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims description 4
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 claims description 4
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims description 4
- 102100027670 Islet amyloid polypeptide Human genes 0.000 claims description 4
- 102000010638 Kinesin Human genes 0.000 claims description 4
- 108010063296 Kinesin Proteins 0.000 claims description 4
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 4
- 229940123573 Protein synthesis inhibitor Drugs 0.000 claims description 4
- 101100485284 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRM1 gene Proteins 0.000 claims description 4
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 claims description 4
- 101150094313 XPO1 gene Proteins 0.000 claims description 4
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 claims description 4
- 108010011559 alanylphenylalanine Proteins 0.000 claims description 4
- 229960002173 citrulline Drugs 0.000 claims description 4
- 230000000368 destabilizing effect Effects 0.000 claims description 4
- 108020001096 dihydrofolate reductase Proteins 0.000 claims description 4
- 229930188854 dolastatin Natural products 0.000 claims description 4
- 108700002148 exportin 1 Proteins 0.000 claims description 4
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 4
- 229940043355 kinase inhibitor Drugs 0.000 claims description 4
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 4
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 4
- 210000003470 mitochondria Anatomy 0.000 claims description 4
- 230000030147 nuclear export Effects 0.000 claims description 4
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 4
- 230000000861 pro-apoptotic effect Effects 0.000 claims description 4
- 239000003207 proteasome inhibitor Substances 0.000 claims description 4
- 239000000007 protein synthesis inhibitor Substances 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 238000006276 transfer reaction Methods 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 150000001413 amino acids Chemical group 0.000 claims 9
- FUHCFUVCWLZEDQ-UHFFFAOYSA-N 1-(2,5-dioxopyrrolidin-1-yl)oxy-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid Chemical compound O=C1CCC(=O)N1OC(=O)C(S(=O)(=O)O)CCSSC1=CC=CC=N1 FUHCFUVCWLZEDQ-UHFFFAOYSA-N 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 172
- 238000000034 method Methods 0.000 description 54
- 102000014914 Carrier Proteins Human genes 0.000 description 22
- 206010028980 Neoplasm Diseases 0.000 description 22
- 108091008324 binding proteins Proteins 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 125000000539 amino acid group Chemical group 0.000 description 20
- 201000011510 cancer Diseases 0.000 description 19
- 206010027476 Metastases Diseases 0.000 description 17
- 230000009401 metastasis Effects 0.000 description 17
- 201000010099 disease Diseases 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 230000003993 interaction Effects 0.000 description 10
- 235000018417 cysteine Nutrition 0.000 description 9
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 9
- 210000002889 endothelial cell Anatomy 0.000 description 8
- 230000017854 proteolysis Effects 0.000 description 8
- 239000004472 Lysine Substances 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 206010039491 Sarcoma Diseases 0.000 description 6
- 230000000593 degrading effect Effects 0.000 description 6
- 108091070501 miRNA Proteins 0.000 description 6
- 239000002679 microRNA Substances 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- AFZIRBOYYNKYFJ-UHFFFAOYSA-N 4-pyridin-2-ylsulfanylpentanoic acid Chemical compound OC(=O)CCC(C)SC1=CC=CC=N1 AFZIRBOYYNKYFJ-UHFFFAOYSA-N 0.000 description 3
- 102100032187 Androgen receptor Human genes 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 3
- 206010065305 Cancer in remission Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 108091027967 Small hairpin RNA Proteins 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 108010080146 androgen receptors Proteins 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 108010044540 auristatin Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 239000000562 conjugate Substances 0.000 description 3
- 230000003413 degradative effect Effects 0.000 description 3
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 3
- 102000015694 estrogen receptors Human genes 0.000 description 3
- 108010038795 estrogen receptors Proteins 0.000 description 3
- 208000013210 hematogenous Diseases 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000001926 lymphatic effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 210000000663 muscle cell Anatomy 0.000 description 3
- 239000002924 silencing RNA Substances 0.000 description 3
- 239000004055 small Interfering RNA Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 229940125644 antibody drug Drugs 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025001193A JP2025061007A (ja) | 2019-02-27 | 2025-01-06 | 抗ｔｍ４ｓｆ１抗体を含む抗体薬物コンジュゲートおよびそれを使用する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962811411P | 2019-02-27 | 2019-02-27 | |
| US62/811,411 | 2019-02-27 | ||
| US202062967377P | 2020-01-29 | 2020-01-29 | |
| US62/967,377 | 2020-01-29 | ||
| PCT/US2020/020207 WO2020176794A1 (en) | 2019-02-27 | 2020-02-27 | Antibody-drug conjugates comprising anti-tm4sf1 antibodies and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025001193A Division JP2025061007A (ja) | 2019-02-27 | 2025-01-06 | 抗ｔｍ４ｓｆ１抗体を含む抗体薬物コンジュゲートおよびそれを使用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022522007A JP2022522007A (ja) | 2022-04-13 |
| JPWO2020176794A5 true JPWO2020176794A5 (enExample) | 2023-02-21 |
Family
ID=72238523
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021550149A Pending JP2022522007A (ja) | 2019-02-27 | 2020-02-27 | 抗ｔｍ４ｓｆ１抗体を含む抗体薬物コンジュゲートおよびそれを使用する方法 |
| JP2025001193A Pending JP2025061007A (ja) | 2019-02-27 | 2025-01-06 | 抗ｔｍ４ｓｆ１抗体を含む抗体薬物コンジュゲートおよびそれを使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025001193A Pending JP2025061007A (ja) | 2019-02-27 | 2025-01-06 | 抗ｔｍ４ｓｆ１抗体を含む抗体薬物コンジュゲートおよびそれを使用する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12428477B2 (enExample) |
| EP (1) | EP3930767A4 (enExample) |
| JP (2) | JP2022522007A (enExample) |
| CN (1) | CN113874051A (enExample) |
| AU (1) | AU2020228060A1 (enExample) |
| CA (1) | CA3131391A1 (enExample) |
| MX (1) | MX2021010254A (enExample) |
| WO (1) | WO2020176794A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3213065A1 (en) * | 2021-03-26 | 2022-09-29 | Paul A. JAMINET | Maytansine-antibody conjugates and methods of using same |
| WO2023056069A1 (en) * | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| WO2023073599A1 (en) * | 2021-10-28 | 2023-05-04 | Novartis Ag | Engineered fc variants |
| WO2025059546A1 (en) * | 2023-09-13 | 2025-03-20 | Trustees Of Tufts College | Proteolysis-targeting chimera tumor vaccine |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
| DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040214872A1 (en) | 2002-09-26 | 2004-10-28 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| AR042485A1 (es) | 2002-12-16 | 2005-06-22 | Genentech Inc | Anticuerpo humanizado que se une al cd20 humano |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| WO2005097832A2 (en) | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| CN102746404B (zh) | 2004-11-12 | 2016-01-20 | 赞科股份有限公司 | 对FcRn的结合被改变的Fc变体 |
| CN101454461A (zh) | 2005-11-16 | 2009-06-10 | Ambrx公司 | 包括非天然氨基酸的方法和组合物 |
| NZ568578A (en) | 2005-12-14 | 2011-10-28 | Ambrx Inc | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| WO2007079130A2 (en) | 2005-12-30 | 2007-07-12 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| US20090093405A1 (en) | 2006-01-19 | 2009-04-09 | Ambrx, Inc. | Non-Natural Amino Acid Polypeptides Having Modified Immunogenicity |
| JP2010512800A (ja) | 2006-12-18 | 2010-04-30 | アンブルックス，インコーポレイテッド | 非天然のアミノ酸およびポリペプチドを含んでいる組成物、これらが関連する方法、ならびにこれらの利用 |
| AU2007341997A1 (en) | 2006-12-28 | 2008-07-10 | Ambrx, Inc. | Phenazine and quinoxaline substituted amino acids and polypeptides |
| DK2175884T3 (en) | 2007-07-12 | 2016-09-26 | Gitr Inc | Combination USING GITR BINDING MOLECULES |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| JP5620106B2 (ja) * | 2007-10-24 | 2014-11-05 | 株式会社糖鎖工学研究所 | 増強されたエフェクター機能を有するポリペプチド |
| HRP20150279T1 (hr) | 2007-12-26 | 2015-05-08 | Xencor, Inc. | Fc inaäśice s promijenjenim vezanjem na fcrn |
| PL2250279T3 (pl) | 2008-02-08 | 2016-11-30 | Przeciwciała anty-ifnar1 o zmniejszonym powinowactwie do liganda fc | |
| PT2337846T (pt) | 2008-09-26 | 2018-04-05 | Ambrx Inc | Vacinas e microrganismos dependentes da replicação de aminoácidos não naturais |
| WO2010073694A1 (ja) | 2008-12-25 | 2010-07-01 | 国立大学法人東京大学 | 抗tm4sf20抗体を用いた癌の診断と治療 |
| EP2711018A1 (en) * | 2009-06-22 | 2014-03-26 | MedImmune, LLC | Engineered Fc regions for site-specific conjugation |
| SI2691417T2 (sl) | 2011-03-29 | 2025-05-30 | Roche Glycart Ag | FC variante protitelesa |
| JP6152090B2 (ja) | 2011-04-21 | 2017-06-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ | 視神経脊髄炎を処置するための組成物および方法 |
| US9796754B2 (en) | 2011-05-27 | 2017-10-24 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| SG10201605293PA (en) | 2011-05-27 | 2016-08-30 | Ambrx Inc | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| CN104203978A (zh) * | 2011-10-24 | 2014-12-10 | 艾伯维股份有限公司 | 针对硬化蛋白的免疫结合剂 |
| BR112015029788B1 (pt) | 2013-05-31 | 2024-01-02 | Zymeworks Inc | HETERO-MULTÍMERO, USO E MÉTODO PARA PREPARAR DO MESMO, COMPOSIÇÃO FARMACÊUTICA E MÉTODO PARA REDUZIR FUNÇÃO EFETORA DE UM CONSTRUTO IgG FC |
| WO2015054427A1 (en) * | 2013-10-10 | 2015-04-16 | Beth Israel Deaconess Medical Center, Inc. | Tm4sf1 binding proteins and methods of using same |
| KR102367876B1 (ko) | 2013-11-22 | 2022-02-24 | 사브레 테라퓨틱스 엘엘씨 | 오토탁신 억제제 화합물 |
| SG10201912986PA (en) | 2014-05-28 | 2020-02-27 | Agenus Inc | Anti-gitr antibodies and methods of use thereof |
| SI3268047T1 (sl) * | 2015-03-09 | 2024-02-29 | Heidelberg Pharma Research Gmbh | Konjugati amatoksin-protitelo |
| CA2949033C (en) * | 2015-11-30 | 2025-05-06 | Pfizer Inc. | ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION |
| CN108884128A (zh) * | 2016-02-02 | 2018-11-23 | 梅迪托普生物科学有限公司 | 抗egfr抗体药物缀合物 |
| WO2019046338A1 (en) | 2017-08-28 | 2019-03-07 | Angiex, Inc. | ANTI-TM4SF1 ANTIBODIES AND METHODS OF USE |
| WO2019241430A2 (en) * | 2018-06-12 | 2019-12-19 | Angiex, Inc. | Antibody-oligonucleotide conjugates |
| MX2022011958A (es) | 2020-03-27 | 2023-01-11 | Angiex Inc | Conjugados de anticuerpo degradador y métodos de uso de los mismos. |
| WO2021222783A1 (en) | 2020-05-01 | 2021-11-04 | Angiex, Inc. | Anti-tm4sf1 antibody drug conjugates and methods of using same |
| WO2022026915A2 (en) | 2020-07-31 | 2022-02-03 | Angiex, Inc. | Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same |
| WO2022046941A1 (en) | 2020-08-26 | 2022-03-03 | Angiex, Inc. | Antimitotic tetrapeptide-antibody conjugates and methods of using same |
-
2020
- 2020-02-27 JP JP2021550149A patent/JP2022522007A/ja active Pending
- 2020-02-27 WO PCT/US2020/020207 patent/WO2020176794A1/en not_active Ceased
- 2020-02-27 MX MX2021010254A patent/MX2021010254A/es unknown
- 2020-02-27 CN CN202080031892.5A patent/CN113874051A/zh active Pending
- 2020-02-27 AU AU2020228060A patent/AU2020228060A1/en active Pending
- 2020-02-27 EP EP20762413.1A patent/EP3930767A4/en active Pending
- 2020-02-27 CA CA3131391A patent/CA3131391A1/en active Pending
- 2020-02-27 US US17/434,315 patent/US12428477B2/en active Active
-
2025
- 2025-01-06 JP JP2025001193A patent/JP2025061007A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7585230B2 (ja) | バイパラトピックＦＲ－α抗体及びイムノコンジュゲート | |
| JP5925875B2 (ja) | 抗体−薬剤コンジュゲート | |
| CN105585630B (zh) | 具有修改的等电点的抗体 | |
| CN104936617B (zh) | Cd33抗体及其在治疗癌症中的用途 | |
| JP2016518332A5 (enExample) | ||
| JP2018501781A5 (enExample) | ||
| JP2018134080A (ja) | イムノコンジュゲートを作製する抗体を修飾するための特定部位 | |
| JP2020534351A5 (enExample) | ||
| US20250127793A1 (en) | Conjugates of surrogate light chain constructs | |
| JP2025061007A5 (enExample) | ||
| JPWO2020176794A5 (enExample) | ||
| AU2020325753B2 (en) | Biopharmacuetical compositions and related methods | |
| CN116669772A (zh) | Gpc3结合剂、其缀合物以及使用它们的方法 | |
| JPWO2021108693A5 (enExample) | ||
| CN117120097A (zh) | 内化的生物活性化合物缀合物的选择性药物释放 | |
| JPWO2020223221A5 (enExample) | ||
| WO2023187130A1 (en) | Activatable bispecific anti-cd3 and anti-pd-l1 proteins and uses thereof | |
| JPWO2022204568A5 (enExample) | ||
| JPWO2023026235A5 (enExample) | ||
| RU2824761C2 (ru) | Биофармацевтические композиции и связанные с ними способы | |
| RU2832083C2 (ru) | Бипаратопные fr-альфа антитела и иммуноконъюгаты | |
| RU2023100251A (ru) | Антитело против клаудина 18.2 и его конъюгат антитело-лекарственное средство | |
| TW202511288A (zh) | Il-23抗體組合物及使用方法 | |
| TW202411249A (zh) | 抗體－藥物偶聯物的製備方法 | |
| JP2024540536A (ja) | Ｇｐｃ３結合剤、そのコンジュゲートおよびその使用方法 |